Peter Maag News Today

Just how high can the great firewall in china really go . But first, to our top story, the u. S. Government is increasing its scrutiny of big Tech Companies. On top of the department of justice and federal trade commission dividing oversight for possible probes into google, facebook, apple, and amazon, the house judiciary says it will spearhead its own investigation into possible antitrust practices. House lawmakers plan to hold hearings on the matter, a move endorsed by House Majority leader na...

Locking down its deliveries the keyes are drones to amazon locking down its deliveries . Shares tumbled at the start of the week after news broke these companies could be the target of antitrust probes. Are les case, they the department of justice is mulling an antitrust probe and has restriction over a potential apple pro. Meanwhile probe. Meanwhile, the ftc is looking at whether apple practices harm competition. Google makes up over half of digital ad revenue and their closest competitor amazo...

We take a look at the ecommerce giants plan. Of top story, shares alphabet, facebook, apple, and amazon tumbled at the start of the week after news broke these companies could be the target of antitrust probes. In googles case, they are the department of justice is mulling an antitrust probe and has restriction over a potential apple probe. They now reportedly have jurisdiction over a potential apple probe. Meanwhile, the ftc is looking at whether apple practices harm competition in the digital ...

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies...

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The...

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurologyStrong balance sheet, bolstered by recent public offering, expected to fund operations into...

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered,...

BioPharma

Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.